retatrutide weight loss results clinical trials Eli Lilly's shows promising in phase 3 trial Effects of once-weekly subcutaneous retatrutide

TG, serum triglycerides

FDA approved Zepbound (weight loss) in November 2023, Mounjaro (diabetes) in May 2022

This reassures the audience about the safety and effectiveness of these therapies, instilling a sense of security and confidence

Efforts to tighten regulations have repeatedly failed in the legislature, leaving critics warning that these are not haircuts theyre medical procedures. Prescription Drug Affordability Board (PDAB) activity States in dark red have passed legislation to create a PDAB

The counterargument is that morning injection means you lose your appetite during the hours when you should be eating protein-rich meals to preserve muscle mass